| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9855f853f24337072ce02f44383942c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70f71261431fa0871b47ed2e0da7b4ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b65624ee4f8c8878257c719b891719b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ed2e3189a0649929f9e38c436a92846 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N24-00 |
| filingDate |
2011-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8e5c83738339060cf4ae414936e6e98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31c2fe73305f200d31b9a443bcd47211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31c17b10d430e3bcf3a1d85c39a08bcc |
| publicationDate |
2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8119417-B2 |
| titleOfInvention |
Monitoring treatment of head and neck cancer patients with drugs EGFR pathway using mass spectrometry of patient samples |
| abstract |
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10037874-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11710539-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10217620-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011208433-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11150238-B2 |
| priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |